Form 4: Orchestra BioMed CFO's Tax Withholding Transaction

Orchestra BioMed's CFO, Andrew Taylor, had 3,452 shares withheld by the company to cover tax obligations related to restricted stock unit vesting.

Summary

• Andrew Lawrence Taylor, Chief Financial Officer of Orchestra BioMed Holdings, Inc. (OBIO), reported a transaction on January 2, 2026.
• The transaction involved the disposition of 3,452 shares of common stock, par value $0.0001 per share.
• These shares were withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• The price per share for the withheld shares was $4.31.
• No shares were sold in the open market as a result of this vesting and tax satisfaction.
• Following this transaction, Mr. Taylor beneficially owns 451,493 shares of common stock.

Sentiment

Score: 5

Explanation: Neutral. This is a routine compliance filing for an executive's equity compensation and tax withholding, which is a normal part of executive compensation packages and does not indicate any significant positive or negative operational or financial news for the company.

Positives

• The transaction is a routine tax withholding event, indicating the vesting of restricted stock units for the CFO, which is a form of compensation.
• No shares were sold in the open market, suggesting the CFO is retaining his equity position beyond the tax obligation.

Negatives

• The reduction in direct beneficial ownership by 3,452 shares, although for tax purposes, slightly decreases the CFO's direct stake.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• "Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units. No shares were sold in the market as a result of the vesting of these restricted stock units and the satisfaction of tax withholding obligations."

Industry Context

This is a standard insider transaction filing (Form 4) related to executive compensation and tax obligations, which is common across all publicly traded companies. It does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: This is a routine transaction related to executive compensation and tax obligations, which is generally expected and does not directly impact the company's operational performance or financial health. It reflects the vesting of previously granted equity awards.

Key Dates

Recommendation

This Form 4 filing details a routine tax withholding transaction for the CFO's restricted stock units. It is a standard compliance event and does not provide new information that would fundamentally alter the investment thesis for Orchestra BioMed Holdings. Therefore, a 'hold' recommendation is appropriate as this filing alone does not warrant a change in investment strategy.

Keywords

Orchestra BioMed Holdings, OBIO, Andrew Taylor, CFO, Form 4, Insider Transaction, Restricted Stock Units, Tax Withholding, Equity Compensation